Total
0
Shares
Nuheara (ASX:NUH) - CEO, Justin Miller
CEO, Justin Miller
Source: Nuheara
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Nuheara (NUH) has surpassed 4000 units in preorders for its newest product, IQbuds² MAX
  • The IQbuds² MAX are Nuheara’s award-winning, wireless, personalised hearing technology
  • Most preorders have come from the European and North American markets, which represent over 70 per cent of all sales
  • The company has credited being able to sell over 4000 units in just four months to its direct-to-consumer model and marketing strategies
  • In fact, year-to-date unit sales for the current financial year now exceeds the total sales in the 2019 financial year by 40 per cent
  • Nuheara is up 9.09 per cent and shares are trading for 2.4 cents each

Nuheara (NUH) has surpassed over 4000 units in preorders for its newest product, IQbuds² MAX.

FY2020 year-to-date unit sales now exceed the total sales in FY19 by 40 per cent.

The IQbuds² MAX are Nuheara’s award-winning, wireless, personalised hearing technology.

These earbuds are customised specifically to the wearer’s wants and needs. It features active noise cancellation (which can be adjusted), voice assistants, tap touch and TV volume control, phone calls, a long battery life, and more.

“The fact that we have built a global online platform to reach our consumers directly, and that we have now sold more than 4000 IQbuds² MAX in just four months, demonstrates how relevant and resilient our sales and marketing strategies are — even in economies drastically impacted by COVID 19,” CEO Justin Miller said.

Reportedly, most of the pre-orders have come from the European and North American markets which represent over 70 per cent of all sales.

Interestingly, while other major hearing aid companies experienced up to an 80 per cent slump in sales during April, Nuheara achieved broad sales year-on-year growth of 251 per cent for the U.S., 162 per cent for the United Kingdom and 198 per cent for Canada.

The company attributes the growth in orders to its direct-to-consumer sales model that has continued to grow, even during COVID-19.

“The deployment of our marketing efforts hasn’t even reached their peak, and once we are able to increase our marketing spend, we expect to see stronger customer reach than we have already,” Justin said.

Nuheara is up 9.09 per cent and shares are trading for 2.4 cents each at 10:14 am AEST.

NUH by the numbers
More From The Market Herald

" AL3D (ASX:AL3) sells Arcemy 3D printer to University of Queensland

AL3D Limited (AL3) has sold one of its Arcemy WAM printing units to the University of Queensland (UQ) for around $400,000.

" EP&T Global (ASX:EPX) forecasts 85pc ARR growth for FY22

EP&T Global (EPX) expects the company’s annualised recurring revenue (ARR) to grow by 85 per cent in the 2022 financial year.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.